Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Epidermal Growth Factor Receptor
72%
Therapeutic Procedure
72%
Patient
62%
Inpatient
30%
Chemotherapy
29%
Oncology
23%
Non-Small Cell Lung Cancer
23%
Thoracic Oncology
22%
Targeted Therapy
17%
Biological Marker
17%
Disease
13%
Diagnosis
11%
Crizotinib
11%
Overall Survival
10%
Clinical Trial
10%
Mesenchymal-Epithelial Transition
10%
Survival
9%
Neoplasm
9%
Medical Oncology
9%
Anaplastic Lymphoma Kinase
9%
Hepatocellular Carcinoma
9%
Metastatic Carcinoma
9%
Next Generation Sequencing
8%
Epidermal Growth Factor Receptor 2
8%
Cholangiocarcinoma
8%
Oncogene
8%
Analysis
8%
Prognostic Factor
7%
Network Meta-Analysis
7%
Lung Adenocarcinoma
7%
Mortality
7%
Retrospective Cohort Study
7%
Health Care Cost
7%
Lung Cancer Diagnostics
7%
Systematic Review
7%
Trastuzumab
7%
Phase II Trials
7%
Molecularly Targeted Therapy
7%
Mammalian Target of Rapamycin Inhibitor
7%
Pleura Mesothelioma
7%
Adverse Event
7%
Immunotherapy
5%
Hazard Ratio
5%
Pharmacology, Toxicology and Pharmaceutical Science
Osimertinib
51%
Chemotherapy
51%
Epidermal Growth Factor Receptor
30%
Progression Free Survival
21%
Epidermal Growth Factor Receptor
21%
Protein Tyrosine Kinase Inhibitor
21%
Diseases
14%
Irinotecan
14%
Lazertinib
14%
Non Small Cell Lung Cancer
14%
Toxicity
12%
Epidermal Growth Factor Receptor Kinase Inhibitor
12%
Crizotinib
11%
Gefitinib
9%
Liver Cell Carcinoma
8%
Cisplatin
8%
Lung Cancer
7%
Central Nervous System Metastasis
7%
Potassium Acetate
7%
Drug Metabolizing Enzyme
7%
Breast Cancer
7%
Randomized Controlled Trial
7%
Infigratinib
7%
Dacomitinib
7%
High Performance Liquid Chromatography
7%
Cancer Growth
7%
Nephrotoxicity
7%
Clinical Pharmacokinetics
7%
Glucuronide
7%
microRNA
7%
Nintedanib
7%
Pralatrexate
7%
Entinostat
7%
Docetaxel
7%
Alectinib
7%
Crizotinib
7%
Circulating Tumor DNA
7%
Disease
7%
Chemoradiation Therapy
7%
Tolerability
7%
Metastatic Colorectal Cancer
6%
Neoplasm
6%
Survival Rate
5%
Placebo
5%
Creatinine
5%